Filler-Induced Vascular Occlusion

A Review of The Current Management Protocols and Why Every Practitioner Must Know Them

occlusion is not a theoretical risk. It is a documented, recurring complication that affects practitioners across all levels and all . The number of dermal filler globally has grown by 300% since 2000, and as the number and complexity of procedures increases, the incidence of will likely also .

The of regulation in aesthetic practice in the United has resulted in rising levels of and in regard to and managing events to dermal filler .

The purpose of this piece is not to alarm but to inform. A practitioner who understands the criteria, has the appropriate materials immediately to hand, and has rehearsed the management is in a to act . One who has not is not. The difference in between these two practitioners, in a true vascular occlusion, can be the difference between complete resolution and permanent tissue loss — or permanent vision loss.

Vascular following filler injection occurs through one of two . Direct intravascular injection, where the needle or cannula enters a vessel and filler is deposited into the lumen, produces an event as the filler is carried by blood flow away from the injection site. compression, where filler in the perivascular tissue compresses a vessel from outside, is a slower process but capable of producing ischaemia if the compression is sufficient and sustained.

Both mechanisms produce the same downstream consequence: tissue deprived of blood supply begins to die. The rate of tissue death depends on which vessel is involved, the degree of occlusion, and the speed of intervention. In the skin and soft tissue, the window for effective with hyaluronidase is in hours. In the circulation, it is measured in minutes.

The presentation of varies with the vessel affected and the mechanism involved, but certain signs should trigger immediate response regardless of their severity at initial .

Blanching, a sudden of the skin at or near the site, is the most reliable early sign of arterial . It represents of blood flow to the bed and immediate action even if the patient is not in pain.

Livedo reticularis, a mottled, net-like discolouration of the skin, indicates ischaemia.

refill, assessed by applying pressure to the skin and the speed of colour return, provides a simple bedside of tissue perfusion.

Pain that is to the injection, or pain that develops after an initially pain-free injection, is a significant sign, particularly in high-risk zones.

Visual symptoms, blurring, loss of vision, double vision, or any sudden change in visual acuity or visual field, a separate and more critical category of requiring immediate the occlusion protocol.

The current base for the management of peripheral filler-induced has been synthesised into broadly consistent guidelines across expert groups and consensus documents. Regarding vascular complications, expert panels that hyaluronidase treatment be administered as promptly as possible, with into the lesion, under . If guidance is unavailable, the affected area should be throughout and just beyond the ischaemic field.

Stop the injection immediately. The moment any sign of compromise is recognised, no further should be deposited.

Hyaluronidase — the . Hyalase 1500 IU in 10ml of 0.9% sodium chloride and infiltrate throughout and just beyond the ischaemic field. Repeat every 30 to 60 minutes until is . Total dose is titrated to and multiple vials may be required. The dose in current for a emergency is considerably higher than the doses commonly used for elective filler dissolution — this distinction clinically, and practitioners who carry only small of hyaluronidase may be inadequately equipped for a true emergency.

Warm and massage. Apply gentle heat and firm to promote and through the affected tissue.

Aspirin. Consider 300mg stat followed by 75 to 100mg daily for three to five days if there are no contraindications — its antiplatelet effect the risk of in the affected vessel.

oxygen. Where available, oxygen therapy is an established adjunct for cases of tissue ischaemia that do not resolve promptly with hyaluronidase treatment. It is not accessible, but should be aware of their nearest facility.

. If there is inadequate response to initial hyaluronidase treatment, or if despite treatment, urgent to an emergency department with surgery is required.

A critical note on non-HA fillers. The hyaluronidase protocol applies specifically to acid fillers, the enzyme dissolves the filler and restores blood flow. For Radiesse (calcium hydroxylapatite) and (PLLA), there is no equivalent agent. Even for non-HA fillers, has been administered in vascular occlusion cases, the rationale being that it may reduce perivascular oedema and tissue perfusion even when there is no HA to . The base for this is limited but the clinical logic is sound in an where no reversal agent is available.

vision loss represents a categorically different and more urgent emergency than vascular occlusion. Reversing ophthalmic artery within 90 minutes is crucial to preventing permanent blindness. Vision loss following filler injections results from intravascular embolization, most often affecting the ophthalmic artery.

The mechanism is the retrograde embolisation of filler, under injection pressure, from the facial arterial system into the ophthalmic artery, which shares its origin with the internal carotid artery. The high-risk zones for this complication are well characterised: the glabella, the nasal dorsum and tip, the nasolabial folds near the artery, and the forehead near the supratrochlear and supraorbital vessels. A 2025 systematic review and found that the nasal region, glabella, and forehead were the highest-risk injection sites for overall, with ocular involvement being most commonly associated with nasal and injections.

The most protocol for managing filler-induced vision loss in a non-ophthalmological setting is the protocol, updated in 2025. The EYE-CODE protocol for the non-ophthalmologist provides a structured emergency to retinal artery after intra-arterial of soft tissue fillers, including immediate hyaluronidase at and around the injection site, ocular to reduce intraocular pressure and the embolus, and urgent referral.

The most technically and most in vision loss is retrobulbar hyaluronidase injection — the of hyaluronidase behind the globe, as close as possible to the and retinal arteries.

A 2025 guideline using and micro-CT identified the inferolateral as the safest trajectory for retrobulbar injection, risk to ocular muscles and nerves. The optimal needle trajectory was identified as from the inferolateral rim toward the superior medial quadrant, critical neurovascular structures.

The evidence for its is, however, . A systematic review found improvement in only 3 out of 17 cases treated with retrobulbar hyaluronidase for vision loss from periocular filler injections, the need for studies to its . This limited success rate reflects the fundamental challenge: filler that has been embolised into the through pressure is not easily reached by extravascularly hyaluronidase, which must through tissue planes to reach intravascular filler.

Retrobulbar is an option if vision is not by initial measures. The is associated with inherent risks including and optic nerve damage, which the should consider before deciding in which cases the procedure is necessary. are advised to practise this on a cadaver before encountering it in a clinical .

The honest on retrobulbar hyaluronidase is this: it should be attempted in cases of filler-induced vision loss where other have not restored vision, and the window is still open, because the consequences of not acting are permanent blindness. But it should be only by who have in the technique, and it should be accompanied by immediate rather than for it.

hyaluronidase, several have been described in the management of filler-induced ocular ischaemia. has included vasodilators, oral aspirin, hyperbaric oxygen therapy, ocular to reduce pressure, and carbonic to increase retinal blood flow. Ophthalmological intraocular pressure and blood flow should be with involvement.

The consistent across all published is speed — every measure should be initiated as as possible, specialist sought without delay, and the to a facility with appropriate if the treating practitioner cannot them.

The described above are the response to a that should, wherever possible, be . The preventative with the base are well .

Knowledge of the relevant anatomy is non-negotiable, the danger zones, the depths at which vessels run, the territories they supply. Slow, of small volumes, rather than bolus deposits, reduces the risk of intravascular . before injection, while not universally adopted and not infallible, is appropriate in high-risk zones. The use of rather than needles in anatomically complex areas but does not eliminate the risk. And the immediate recognition of the early signs of vascular compromise — rather than to inject in the hope that the blanching will resolve — is the most important practitioner of all.

complications such as vascular occlusion and immediate, treatment. Aesthetic practitioners should be versed in using hyaluronidase and dosage .

This is not . It is the minimum standard. Every practitioner who dermal fillers should carry vials of hyaluronidase on site, know the recognition criteria for vascular occlusion, have a written emergency protocol, know the location of the nearest oxygen facility, and have a direct line to ophthalmological services. Annual drills are increasingly in guidance from and should be considered best practice universally.

The practitioner who has never encountered a occlusion and therefore concludes that is has confused the rarity of an event with the of being for it. These are not the same thing. And the patient who a vascular in an clinic pays the price for that .

The views expressed in are the author’s own and reflect their and in medicine.

References

1. Davies E. Guideline for the of Acid Vascular . Journal of Clinical and Aesthetic . 2021;14(5).

2. Kroumpouzos G, Treacy P. for Dermal Filler Complications: Review of Applications and Dosage Recommendations. JMIR Dermatology. 2024;7:e50403.

Barbarino S, Khalifian S, Fezza J. EYE-CODE for the for Treatment of Retinal Artery After Intra-Arterial Injection of Soft-Tissue Fillers: 2025 Update. Journal of . 2025;24(7):e70336.

4. Yi et al. Guideline for Retrobulbar . Journal of Cosmetic Dermatology. 2025.

5. N et al. Hyaluronidase in Hyaluronic OnabotulinumtoxinAAbobotulinumtoxinAIncobotulinumtoxinAPrabotulinumtoxinALetibotulinumtoxinARimabotulinumtoxinBHyaluronic Acid FillersCalcium Hydroxylapatite FillersPoly-L-lactic Acid FillersPolymethylmethacrylate FillersAutologous Fat GraftingForehead Lines TreatmentGlabellar Frown Lines TreatmentCrow’s Feet TreatmentBunny Lines TreatmentChemical Brow LiftLip FlipGummy Smile CorrectionMasseter ReductionJaw SlimmingDimpled Chin SmoothingCobblestone Chin SmoothingNefertiti Neck LiftMicro-BotoxMesotoxHyperhidrosis TreatmentChronic Migraine ReliefBruxism TreatmentTMJ TreatmentCervical Dystonia TreatmentNeck Spasm TreatmentBlepharospasm TreatmentLip AugmentationLip ContouringCheekbone EnhancementTear Trough FillersNasolabial Fold SofteningMarionette Line FillersLiquid RhinoplastyNon-Surgical Nose JobJawline ContouringJawline DefinitionChin AugmentationTemple VolumisingHand RejuvenationAcne Scar Subcision Filling-Induced Ocular Vascular Occlusion: Efficacy, Challenges, and for Clinical Practice. Aesthetic . 2025;49(5):1458–1468.

6. Chakhachiro A, Waseem M. Risk Factor Analysis for Vascular After Dermal Filler Injections: A Systematic Review and . Cureus. 2025. [

7. Wang et al. Hyaluronic acid filler-induced vascular occlusion — Three case reports and overview of prevention and treatment. Journal of Cosmetic Dermatology. 2024.

8. Italian Consensus Statement: The Use of Hyaluronidase in Hyaluronic Acid Filler Complications. JOJ Dermatology and Cosmetics. 2025;6(5):555696.

Botulinum Toxin — The Dose-Response Relationship and What It Means for Clinical Practice

6 Esher Park Avenue
Esher, Surrey KT10 9NP

Tel: ‬
Tel: ‭ ‬

© 2026
The Cosmetic Doctors
Company Ltd
Company no.